NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 6.42% |
| NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 4.66% |
| BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 4.60% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 4.43% |
| RHHBY | Roche Holding Ltd ADR | Healthcare | Drug Manufacturers - General | 4.28% |
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 4.16% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 3.92% |
| GMAB | Genmab AS | Healthcare | Biotechnology | 3.81% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 3.50% |
| NUVL | Nuvalent Inc | Healthcare | Biotechnology | 3.42% |
| UMRX | Cogent Biosciences Inc | Healthcare | Biotechnology | 3.40% |
| ONC | BeiGene, Ltd. | Healthcare | Biotechnology | 3.09% |
| IMNM | Immunome Inc | Healthcare | Biotechnology | 3.05% |
| IMGN | ImmunoGen Inc | Healthcare | Biotechnology | 3.00% |
| CELC | Celcuity LLC | Healthcare | Biotechnology | 2.71% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 2.55% |
| ACLX | Arcellx Inc | Healthcare | Biotechnology | 2.42% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 2.41% |
| EXEL | Exelixis Inc | Healthcare | Biotechnology | 2.27% |
| BGNE | BeiGene Ltd | Healthcare | Biotechnology | 2.25% |